RYTM · CIK 0001649904
What Rhythm Pharmaceuticals, Inc. told the SEC could break it.
Rhythm is a one-product company concentrated on both who buys it and who makes it. It has focused substantially all of its resources on a single molecule, setmelanotide (sold as IMCIVREE) — its only approved product, accounting for about $422.5 million in cumulative revenue — so its fortunes ride on that one drug's continued success and label expansions. Its revenue is also extremely customer-concentrated: a single U.S. customer generated about 69% of revenue in 2025 (74% in 2024), one international customer another 10%, and a single customer made up 56% of accounts receivable. And because it has no in-house manufacturing, it depends on third-party manufacturers and suppliers for IMCIVREE, whose inability to meet its supply requirements could materially affect operations.
3 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Customer concentration
- single US customer = 69% of revenue; one international = 10%high
Rhythm's revenue is extremely concentrated: a single U.S. customer generated ~69% of revenue in 2025 (74% in 2024), one international customer another ~10%, and 56% of accounts receivable was from a single customer.
“For the years ended December 31, 2025 and 2024, approximately 69 % and 74 %, respectively, of all of the Company's revenue was generated from a single customer in the United States. Additionally, a single international customer also generated approximately 10 % of the Company's revenue during the year ended December 31, 2025.”
SEC filing →As of 2026
Other disclosures
- single-product dependence on setmelanotide / IMCIVREEhigh
Rhythm has focused substantially all of its resources on a single molecule, setmelanotide (IMCIVREE) — its only approved product and ~$422.5M of cumulative revenue — making the business dependent on that one product's continued success and label expansions.
“Since our inception, we have focused substantially all our efforts and financial resources on the research and development of setmelanotide, which is approved by the FDA and Health Canada and authorized by the EC and the MHRA, as noted above, and is in development to address patients affected by several other indications.”
SEC filing →As of 2026
Supplier concentration
- third-party manufacturers/suppliers for IMCIVREE (no in-house manufacturing)medium
Rhythm relies on third-party manufacturers and suppliers for the manufacture and supply of IMCIVREE; their inability to fulfill supply requirements could materially impact operations.
“The Company relies on third-party manufacturers and suppliers for manufacturing and supply of its product. The inability of the suppliers or manufacturers to fulfill supply requirements of the Company could materially impact future operat”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its suppliers
LG Chem, Ltd.
“On January 4, 2024, we announced that we entered into a global licensing agreement with LG Chem, Ltd., or LGC, a leading global company headquartered in South Korea that specializes in life sciences as one of its core businesses, for bivamelagon, an investigational oral small molecule MC4R agonist now in a Phase 2 clinical trial.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch